Progress of anticoagulant therapy of the patients with mechanical prosthetic valve replacement
10.7507/1007-4848.201511034
- VernacularTitle:10.7507/1007-4848.201511034
- Author:
HE Fan
1
,
2
;
XIAO Xijun
3
Author Information
1. 1. Department of Cardiovascular Surgery, West China Hospital of Sichuan University, Chengdu, 610041, P.R.China
2. 2. Heart Center of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310020, P.R.China
3. Department of Cardiovascular Surgery, West China Hospital of Sichuan University, Chengdu, 610041, P.R.China
- Publication Type:Journal Article
- Keywords:
Mechanical heart valve replacement;
early anticoagulation;
warfarin
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2017;24(11):896-901
- CountryChina
- Language:Chinese
-
Abstract:
The patients with mechanical prosthetic valve replacement need anticoagulant therapy for all their life. The incidence of thromboembolism and anticoagulation-related bleeding events still account for major postoperative complications after mechanical heart valve replacement. Most of the complications happen in the first half year after operation. Therefore, early anticoagulation therapy is very important. Of course, so far most guidelines focus stating their opinions on long-term anticoagulant therapy. However, there is no consensus about anticoagulant therapy in the early period of postoperation. In this review, we summarize early anticoagulant therapy of the patients with mechanical heart valve replacement through consulting domestic and abroad relevant research in recent years and give an overview of the present situations of early anticoagulant therapy.
